Entrada Therapeutics Reports Q1 2026 Earnings and Positive DMD Trial Results
Entrada Therapeutics, Inc. (TRDA) held its Q1 2026 earnings call on May 7, 2026, revealing mixed financial results alongside significant clinical progress. The company reported an earnings per share (EPS) of -$0.95, beating estimates by $0.07, but revenue fell to $875,000, missing projections by $2.04 million and representing a 95.74% year-over-year decline. Despite the financial miss, management highlighted positive top-line results from Cohort 1 of the Phase I/II ELEVATE-44-201 study. This trial evaluates ENTR-601-44 in participants living with Duchenne muscular dystrophy (DMD). CEO Dipal Doshi and President of R&D Dr. Natarajan Sethuraman joined Chief Corporate Affairs Officer Karla MacDonald to discuss these developments. The call featured questions from analysts at major firms including Oppenheimer, Evercore ISI, TD Cowen, Goldman Sachs, William Blair, and Cantor Fitzgerald. The presentation emphasized the potential of their oligonucleotide conjugate platform while acknowledging the current revenue challenges. Forward-looking statements were made regarding future performance, subject to standard risks and uncertainties outlined in SEC filings.
Wire timeline
Entrada Therapeutics Reports Q1 2026 Earnings and Positive DMD Trial Results
Entrada Therapeutics, Inc. (TRDA) held its Q1 2026 earnings call on May 7, 2026, revealing mixed financial results alongside significant clinical progress. The company reported an earnings per share (EPS) of -$0.95, beating estimates by $0.07, but revenue fell to $875,000, missing projections by $2.04 million and representing a 95.74% year-over-year decline. Despite the financial miss, management highlighted positive top-line results from Cohort 1 of the Phase I/II ELEVATE-44-201 study. This trial evaluates ENTR-601-44 in participants living with Duchenne muscular dystrophy (DMD). CEO Dipal Doshi and President of R&D Dr. Natarajan Sethuraman joined Chief Corporate Affairs Officer Karla MacDonald to discuss these developments. The call featured questions from analysts at major firms including Oppenheimer, Evercore ISI, TD Cowen, Goldman Sachs, William Blair, and Cantor Fitzgerald. The presentation emphasized the potential of their oligonucleotide conjugate platform while acknowledging the current revenue challenges. Forward-looking statements were made regarding future performance, subject to standard risks and uncertainties outlined in SEC filings.
All Articles on Seeking Alpha